Compare MMYT & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MMYT | FOLD |
|---|---|---|
| Founded | 2000 | 2002 |
| Country | India | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.5B |
| IPO Year | 2010 | 2006 |
| Metric | MMYT | FOLD |
|---|---|---|
| Price | $43.39 | $14.49 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $101.00 | $27.25 |
| AVG Volume (30 Days) | 896.9K | ★ 2.5M |
| Earning Date | 05-20-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.83 | $20.50 |
| Revenue Next Year | $17.24 | $18.59 |
| P/E Ratio | $107.67 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $32.67 | $5.66 |
| 52 Week High | $105.23 | $14.50 |
| Indicator | MMYT | FOLD |
|---|---|---|
| Relative Strength Index (RSI) | 44.58 | 74.18 |
| Support Level | $32.67 | $14.21 |
| Resistance Level | $51.24 | N/A |
| Average True Range (ATR) | 2.31 | 0.02 |
| MACD | -0.57 | -0.00 |
| Stochastic Oscillator | 35.27 | 100.00 |
MakeMyTrip Ltd is an online travel company, which provides online booking solutions for day-to-day travel needs. The company's operating segment includes Air ticketing; Hotels and packages; Bus ticketing and Others. It generates maximum revenue from the Hotels and packages segment. The Hotels and packages segments include internet-based platforms, call-centers, and branch offices, which provide holiday packages and hotel reservations. Its Air ticketing segment includes internet-based platforms, provides the facility to book domestic and international air tickets. Geographically, it derives a majority of revenue from India and also has a presence in the United States; South East Asia; Europe, and other countries.
Amicus Therapeutics Inc is a biotechnology company focused to develop and deliver transformative medicines for people living with rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.